ankuankit

ankuankit

Breakout above 2.2? and possible gap fill toward upside. The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:4, with the majority favoring treatment with the drug as monotherapy. FDA decision soon. Risk is traditional sell the news event.

ankuankit

looks like for LT, the market still has good hope to follow its natural trend that is ..